{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:50:03Z","timestamp":1791978603405,"version":"4.4.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"DOI":"10.1208\/s12248-026-01320-0","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:00:31Z","timestamp":1791831631000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Liquid Chromatography\/tandem Mass Spectrometry-based Target Engagement of Lysine-specific Demethylase 1 Inhibitor TAK-418 Through Detecting Covalent Adducts in the Brain"],"prefix":"10.1208","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2818-4621","authenticated-orcid":false,"given":"Kota","family":"Matsumiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5339-8372","authenticated-orcid":false,"given":"Shinji","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7538-6962","authenticated-orcid":false,"given":"Satoru","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9318-4723","authenticated-orcid":false,"given":"Yohei","family":"Kosugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1401-7041","authenticated-orcid":false,"given":"Hisao","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6057-0596","authenticated-orcid":false,"given":"Masaaki","family":"Kakehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8855-454X","authenticated-orcid":false,"given":"Rina","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8483-2673","authenticated-orcid":false,"given":"Nobuyuki","family":"Amano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0303-3177","authenticated-orcid":false,"given":"Atsushi","family":"Nakatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8292-3647","authenticated-orcid":false,"given":"Haruhide","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6812-3651","authenticated-orcid":false,"given":"Hideki","family":"Hirabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"issue":"8","key":"1320_CR1","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/nrd1470","volume":"3","author":"I Kola","year":"2004","unstructured":"Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004;3(8):711\u20135. https:\/\/doi.org\/10.1038\/nrd1470.","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"1320_CR2","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1093\/ijnp\/pyz027","volume":"22","author":"P O'Donnell","year":"2019","unstructured":"O\u2019Donnell P, Rosen L, Alexander R, Murthy V, Davies CH, Ratti E. Strategies to Address Challenges in Neuroscience Drug Discovery and Development. Int J Neuropsychopharmacol. 2019;22(7):445\u20138. https:\/\/doi.org\/10.1093\/ijnp\/pyz027.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"9-10","key":"1320_CR3","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.drudis.2011.12.020","volume":"17","author":"P Morgan","year":"2012","unstructured":"Morgan P, Van Der Graaf PH, Arrowsmith J, Feltner DE, Drummond KS, Wegner CD, et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving phase II survival. Drug Discov Today. 2012;17(9\u201310):419\u201324. https:\/\/doi.org\/10.1016\/j.drudis.2011.12.020.","journal-title":"Drug Discov Today"},{"key":"1320_CR4","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aba1187","author":"R Baba","year":"2021","unstructured":"Baba R, Matsuda S, Arakawa Y, Yamada R, Suzuki N, Ando T, et al. LSD1 enzyme inhibitor TAK-418 unlocks aberrant epigenetic machinery and improves autism symptoms in neurodevelopmental disorder models. Sci Adv. 2021. https:\/\/doi.org\/10.1126\/sciadv.aba1187.","journal-title":"Sci Adv"},{"key":"1320_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114522","volume":"239","author":"Y Hattori","year":"2022","unstructured":"Hattori Y, Matsumoto S, Morimoto S, Daini M, Toyofuku M, Matsuda S, et al. Design, synthesis, and structure-activity relationship of TAK-418 and its derivatives as a novel series of LSD1 inhibitors with lowered risk of hematological side effects. Eur J Med Chem. 2022;239:114522. https:\/\/doi.org\/10.1016\/j.ejmech.2022.114522.","journal-title":"Eur J Med Chem"},{"issue":"46","key":"1320_CR6","doi-asserted-by":"publisher","first-page":"35289","DOI":"10.1074\/jbc.M607411200","volume":"281","author":"F Forneris","year":"2006","unstructured":"Forneris F, Binda C, Dall\u2019Aglio A, Fraaije MW, Battaglioli E, Mattevi A. A highly specific mechanism of histone H3-K4 recognition by histone demethylase LSD1. J Biol Chem. 2006;281(46):35289\u201395. https:\/\/doi.org\/10.1074\/jbc.M607411200.","journal-title":"J Biol Chem"},{"issue":"7","key":"1320_CR7","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nsmb1113","volume":"13","author":"P Stavropoulos","year":"2006","unstructured":"Stavropoulos P, Blobel G, Hoelz A. Crystal structure and mechanism of human lysine-specific demethylase-1. Nat Struct Mol Biol. 2006;13(7):626\u201332. https:\/\/doi.org\/10.1038\/nsmb1113.","journal-title":"Nat Struct Mol Biol"},{"issue":"6","key":"1320_CR8","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/nsmb1255","volume":"14","author":"M Yang","year":"2007","unstructured":"Yang M, Culhane JC, Szewczuk LM, Gocke CB, Brautigam CA, Tomchick DR, et al. Structural basis of histone demethylation by LSD1 revealed by suicide inactivation. Nat Struct Mol Biol. 2007;14(6):535\u20139. https:\/\/doi.org\/10.1038\/nsmb1255.","journal-title":"Nat Struct Mol Biol"},{"issue":"5","key":"1320_CR9","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1002\/med.21350","volume":"35","author":"YC Zheng","year":"2015","unstructured":"Zheng YC, Ma J, Wang Z, Li J, Jiang B, Zhou W, et al. A systematic review of histone lysine-specific demethylase 1 and its inhibitors. Med Res Rev. 2015;35(5):1032\u201371. https:\/\/doi.org\/10.1002\/med.21350.","journal-title":"Med Res Rev"},{"issue":"1","key":"1320_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13072-018-0251-8","volume":"12","author":"BE Collins","year":"2019","unstructured":"Collins BE, Greer CB, Coleman BC, Sweatt JD. Histone H3 lysine K4 methylation and its role in learning and memory. Epigenetics Chromatin. 2019;12(1):7. https:\/\/doi.org\/10.1186\/s13072-018-0251-8.","journal-title":"Epigenetics Chromatin"},{"issue":"8","key":"1320_CR11","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1038\/s41386-018-0300-9","volume":"44","author":"S Matsuda","year":"2019","unstructured":"Matsuda S, Baba R, Oki H, Morimoto S, Toyofuku M, Igaki S, et al. T-448, a specific inhibitor of LSD1 enzyme activity, improves learning function without causing thrombocytopenia in mice. Neuropsychopharmacology. 2019;44(8):1505\u201312. https:\/\/doi.org\/10.1038\/s41386-018-0300-9.","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"1320_CR12","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1021\/acschemneuro.1c00713","volume":"13","author":"R Baba","year":"2022","unstructured":"Baba R, Matsuda S, Maeda R, Murakami K, Yamamoto Y, Nakatani A, et al. Investigating the therapeutic potential of LSD1 enzyme activity-specific inhibition by TAK-418 for social and memory deficits in rodent disease models. ACS Chem Neurosci. 2022;13(3):313\u201321. https:\/\/doi.org\/10.1021\/acschemneuro.1c00713.","journal-title":"ACS Chem Neurosci"},{"issue":"17","key":"1320_CR13","doi-asserted-by":"publisher","first-page":"12680","DOI":"10.1021\/acs.jmedchem.1c00653","volume":"64","author":"S Matsuda","year":"2021","unstructured":"Matsuda S, Hattori Y, Matsumiya K, McQuade P, Yamashita T, Aida J, et al. Design, synthesis, and evaluation of [(18)F]T-914 as a novel positron-emission tomography tracer for lysine-specific demethylase 1. J Med Chem. 2021;64(17):12680\u201390. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00653.","journal-title":"J Med Chem"},{"issue":"1","key":"1320_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s40658-022-00523-6","volume":"10","author":"J Du","year":"2023","unstructured":"Du J, Jones T. Technical opportunities and challenges in developing total-body PET scanners for mice and rats. EJNMMI Phys. 2023;10(1):2. https:\/\/doi.org\/10.1186\/s40658-022-00523-6.","journal-title":"EJNMMI Phys"},{"issue":"1","key":"1320_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1258\/la.2012.011173","volume":"47","author":"AK Alstrup","year":"2013","unstructured":"Alstrup AK, Smith DF. Anaesthesia for positron emission tomography scanning of animal brains. Lab Anim. 2013;47(1):12\u20138. https:\/\/doi.org\/10.1258\/la.2012.011173.","journal-title":"Lab Anim"},{"issue":"26","key":"1320_CR16","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1016\/j.lfs.2005.11.031","volume":"78","author":"VN Barth","year":"2006","unstructured":"Barth VN, Chernet E, Martin LJ, Need AB, Rash KS, Morin M, et al. Comparison of rat dopamine D2 receptor occupancy for a series of antipsychotic drugs measured using radiolabeled or nonlabeled raclopride tracer. Life Sci. 2006;78(26):3007\u201312. https:\/\/doi.org\/10.1016\/j.lfs.2005.11.031.","journal-title":"Life Sci"},{"issue":"4","key":"1320_CR17","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.lfs.2005.04.075","volume":"78","author":"E Chernet","year":"2005","unstructured":"Chernet E, Martin LJ, Li D, Need AB, Barth VN, Rash KS, et al. Use of LC\/MS to assess brain tracer distribution in preclinical, in vivo receptor occupancy studies: dopamine D2, serotonin 2A and NK-1 receptors as examples. Life Sci. 2005;78(4):340\u20136. https:\/\/doi.org\/10.1016\/j.lfs.2005.04.075.","journal-title":"Life Sci"},{"issue":"17-18","key":"1320_CR18","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.lfs.2007.09.005","volume":"81","author":"AB Need","year":"2007","unstructured":"Need AB, McKinzie JH, Mitch CH, Statnick MA, Phebus LA. In vivo rat brain opioid receptor binding of LY255582 assessed with a novel method using LC\/MS\/MS and the administration of three tracers simultaneously. Life Sci. 2007;81(17\u201318):1389\u201396. https:\/\/doi.org\/10.1016\/j.lfs.2007.09.005.","journal-title":"Life Sci"},{"issue":"5","key":"1320_CR19","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1111\/jphp.12030","volume":"65","author":"R Nirogi","year":"2013","unstructured":"Nirogi R, Kandikere V, Bhyrapuneni G, Saralaya R, Ajjala DR, Aleti RR, et al. In-vivo rat striatal 5-HT4 receptor occupancy using non-radiolabelled SB207145. J Pharm Pharmacol. 2013;65(5):704\u201312. https:\/\/doi.org\/10.1111\/jphp.12030.","journal-title":"J Pharm Pharmacol"},{"issue":"1","key":"1320_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-32683-w","volume":"8","author":"R Hansen","year":"2018","unstructured":"Hansen R, Firdaus SJ, Li S, Janes MR, Zhang J, Liu Y, et al. An internally controlled quantitative target occupancy assay for covalent inhibitors. Sci Rep. 2018;8(1):14312. https:\/\/doi.org\/10.1038\/s41598-018-32683-w.","journal-title":"Sci Rep"},{"issue":"13","key":"1320_CR21","doi-asserted-by":"publisher","first-page":"8443","DOI":"10.1021\/acs.analchem.9b01462","volume":"91","author":"N Zheng","year":"2019","unstructured":"Zheng N, Catlett IM, Taylor K, Gu H, Pattoli MA, Neely RJ, et al. Determination of real time in vivo drug receptor occupancy for a covalent binding drug as a clinical pharmacodynamic biomarker by immunocapture-LC-MS\/MS. Anal Chem. 2019;91(13):8443\u201352. https:\/\/doi.org\/10.1021\/acs.analchem.9b01462.","journal-title":"Anal Chem"},{"issue":"7","key":"1320_CR22","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.1021\/acs.jmedchem.0c01937","volume":"64","author":"Y Hattori","year":"2021","unstructured":"Hattori Y, Matsuda S, Baba R, Matsumiya K, Iwasaki S, Constantinescu CC, et al. Design, synthesis, and evaluation of (2-aminocyclopropyl)phenyl derivatives as novel positron emission tomography imaging agents for lysine-specific demethylase 1 in the brain. J Med Chem. 2021;64(7):3780\u201393. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c01937.","journal-title":"J Med Chem"},{"issue":"10","key":"1320_CR23","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1016\/j.febslet.2005.03.015","volume":"579","author":"F Forneris","year":"2005","unstructured":"Forneris F, Binda C, Vanoni MA, Mattevi A, Battaglioli E. Histone demethylation catalysed by LSD1 is a flavin-dependent oxidative process. FEBS Lett. 2005;579(10):2203\u20137. https:\/\/doi.org\/10.1016\/j.febslet.2005.03.015.","journal-title":"FEBS Lett"},{"issue":"12","key":"1320_CR24","doi-asserted-by":"publisher","first-page":"4756","DOI":"10.1111\/bcp.14912","volume":"87","author":"W Yin","year":"2021","unstructured":"Yin W, Arkilo D, Khudyakov P, Hazel J, Gupta S, Quinton MS, et al. Safety, pharmacokinetics and pharmacodynamics of TAK-418, a novel inhibitor of the epigenetic modulator lysine-specific demethylase 1A. Br J Clin Pharmacol. 2021;87(12):4756\u201368. https:\/\/doi.org\/10.1111\/bcp.14912.","journal-title":"Br J Clin Pharmacol"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01320-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-026-01320-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01320-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:03:59Z","timestamp":1791975839000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-026-01320-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":24,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["1320"],"URL":"https:\/\/doi.org\/10.1208\/s12248-026-01320-0","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]},"assertion":[{"value":"12 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"168"}}